A clinical trial to study the effect of Single dose steroid on major hepatectomy

Impact of preoperative single dose Methylprednisolone on Major Hepatectomy in adults

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046832

Enrollment

120

Registered

2022-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: Methylprednisolone: in the study group 500mg Intravenous Methylprednisolone will be given single dose Drug will be given one time (1) at the time of induction of anaesthesia Control In

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing Major Hepatectomy

Exclusion criteria

Exclusion criteria: 1.Patients who deny consenting for study 2.Patients who are on steroids for other conditions 3.Patients undergoing recipient Hepatectomy 4.Patients undergoing Minor hepatectomy/Non anatomic liver resections

Design outcomes

Primary

Measure	Time frame
To compare post operative complicationsTimepoint: Within 90days after Liver resection	—

Secondary

Measure	Time frame
1.peri-operative Mortality 2.Inflammatory marker - CRP at baseline and on POD 1,3 and 5 and during follow up visit 3.Levels of Total Bilirubin,Direct bilirubin,AST,ALT,PT/INR at baseline and on POD 1,3,5 and during follow up visit 4.Length of Hospital stayTimepoint: With in 90days after liver resection	—

Countries

India

Contacts

Public ContactMuddada Vivekananda

Amrita Institute of Medical sciences

ovsudheer@yahoo.com9447129111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026